News and Announcements
PTX-200 Phase 1b/2 Clinical Update Trial
- Published August 26, 2015 5:13PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
26th August 2015, ASX Announcement
- Novel cancer drug PTX-200 shows evidence of safety and antitumor activity when combined with weekly paclitaxel in advanced cancer patients
- Expansion Phase enrollment to shortly commence at Montefiore Medical Center
- Moffitt Cancer Center will now join the study under lead investigator Dr Heather Han
Clinical stage oncology company Prescient Therapeutics (ASX: PTX), today announced encouragingly early clinical data arising from their ongoing Phase 1b/2 clinical study of novel cancer drug PTX-200 trial in breast, lung and esophageal cancer.
The study is currently being conducted as an Investigator Sponsored Trial (IST) under the lead of Professor Joseph Sparano, Professor of Medicine & Obstetrics, Gynecology, and Women’s Health at Montefiore Medical Center and the Albert Einstein College of Medecine and Cancer Center, and has been partially funded by the U.S. National Cancer Institute.
Professor Joseph Sparano said PTX-200 was a highly promising oncology compound and prior studies had yet to fully exploit its potential anticancer activity “In phase 2 study that will begin upon completion of the expansion cohort, we will determine the pathologic complete response rate after PTX200 plus paclitaxel therapy in patients with locally advanced breast cancer- this model has been used in other trials to identify promising new agents and advance their development in a rapid and efficient manner.”
To read the full announcement, please click here.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
